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DOI 10.1016/j.ccr.2009.12.045SUMMARYPML/RARa is of crucial importance in acute promyelocytic leukemia (APL) both pathologically and therapeu-
tically. Using a genome-wide approach, we identified in vivo PML/RARa binding sites in a PML/RARa-induc-
ible cell model. Of the 2979 targeted regions, >62% contained canonical PU.1 motifs and >84% of these
PU.1 motifs coexisted with one or more RARE half (RAREh) sites in nearby regions. Promoters with such
PU.1-RAREh binding sites were transactivated by PU.1. PU.1-mediated transactivation was repressed by
PML/RARa and restored by the addition of all-trans retinoic acid (ATRA). Genes containing such promoters
were significantly represented by genes transcriptionally suppressed in APL and/or reactivated upon treat-
ment with ATRA. Thus, selective targeting of PU.1-regulated genes by PML/RARa is a critical mechanism for
the pathogenesis of APL.INTRODUCTION
Acute promyelocytic leukemia (APL) is pathologically character-
ized by the accumulation of promyelocytic blast cells in the bone
marrow and blood and cytogenetically defined by a typical
t(15;17) (q22;q21) translocation occurring inmost of the patients.
This translocation results in a fusion protein known as the pro-
myelocytic leukemia-retinoic acid receptor a (PML/RARa), which
is capable of blocking cell differentiation at the promyelocytic
stage. Although the pathogenetic importance of PML/RARa in
APL has been recognized for over a decade, the mechanism
by which PML/RARa drives the development of APL is far from
clear. This is largely due to the limited number of PML/RARaSignificance
PML/RARa contributes to the development of APL through
Although previous reports have suggested substantial crosstal
of how this occurs. Through a global approach, we demonst
promoters through both protein-protein interaction and DNA b
Genes with such promoters are involved in hematopoiesis and
targets are significantly enriched in genes transcriptionally su
Thus, selective targeting of PU.1-regulated genes by PML/RA
sion occurring in APL and is essential for the observed differe
186 Cancer Cell 17, 186–197, February 17, 2010 ª2010 Elsevier Inc.target genes identified to date and to the structural and func-
tional complexity of PML/RARa.
The fusion protein retains the oligomerization domain of PML
and the DNA binding and ligand binding domains of RARa. It
exists in multiple complexes including PML/RARa homodimers,
PML/RARa oligomers (containing the homodimers plus one or
two RXR), and PML/RARa-RXR heterodimers (Jansen et al.,
1995). PML/RARa possesses a high affinity for corepressor
molecules such as nuclear receptor corepressor, silencing
mediator of retinoic and thyroid hormone receptors, and histone
deacetylases. Thus, it acts as a strong transcriptional repressor
for its target genes, which are thought to include genes indis-
pensable for myeloid differentiation (Lin et al., 2001). In therepression of genes important in myeloid development.
k between PML/RARa and PU.1, there is little understanding
rate that PML/RARa predominantly targets PU.1-regulated
inding via RARE half sites forming complex binding motifs.
primarily regulated by PU.1. In addition, these PML/RARa
ppressed in APL and/or reactivated after ATRA treatment.
Ra represents a major mechanism of transcriptional repres-
ntiation block.
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acid (ATRA), the ligand for both RARa and PML/RARa, the core-
pressor molecules disassociate from PML/RARa, restoring
expression of genes essential for myeloid differentiation and so
inducing the accumulated promyelocytes to differentiate into
neutrophils.
Since PML/RARa retains the DNA binding domain of RARa, it
has been a long-standing assumption that PML/RARa might
primarily bind to RARa binding sites and thus suppress RARa-
regulated genes. However, this assumption has become less
likely after the observation that myeloid commitment is hardly
affected in various RAR-deficient mice (Collins, 2002). This
observation implies that genes indispensable for myeloid differ-
entiation are probably regulated by transcription factors other
than RARa or any other tested retinoid receptors. Identification
of PML/RARa target genes has been lagging far behind, largely
due to the complexity of DNA sequences recognized by PML/
RARa and to the lack of means to distinguish target genes of
PML/RARa from those of RARa. For instance, heterodimers of
RARa and RXR bind typically to canonical retinoic acid respon-
sive elements (RAREs) composed of direct repeats (DR) of two
[A/G]G[G/T]TCA [RARE half (RAREh)] sites with five (DR5) or
two (DR2) random nucleotides in between. However, it is
important to note that most of the PML/RARa targets reported
to date lack canonical RAREs in their promoter regions, e.g.,
UBE1L, C/EBPb, and BLR1. Moreover, in vitro binding studies
of PML/RARa using a selection/amplification technique have
revealed that PML/RARa may bind to RAREh sites arranged
in different orientations and with widely variable spacing in
between (Kamashev et al., 2004), implying that the DNA binding
spectrum of this fusion protein is more complex and versatile
than previously thought. Furthermore, under certain circum-
stances, PML/RARa is able to interact withmany other transcrip-
tion factors, such as AP-1, GATA2, and Sp1, providing the
potential for the fusion protein to target genes primarily regulated
by other transcription factors and thus adding additional
complexity to the binding spectrum of PML/RARa. For example,
PML/RARa is reported to act as a repressor of AP-1-dependent
transactivation, which can be reversed by the addition of ATRA
(Doucas et al., 1993). Similarly, GATA2-dependent gene tran-
scription appears to be influenced by PML/RARa (Tsuzuki
et al., 2000).
Identification of bona fide and relevant in vivo binding sites of
PML/RARa is obviously a multifaceted issue that requires
a global approach. In the current study, we performed ChIP-
on-chip studies on a PML/RARa-inducible cell model that
mimics cells immediately after the t(15;17) translocation and
the expression of PML/RARa.RESULTS
Identification of In Vivo Binding Regions of PML/RARa
The PR9 cell line, constructed from U937 myeloid precursor
cells, is a PML/RARa-inducible model that provides a system
for studying early events associated with de novo expression
of PML/RARa. To identify chromatin DNA targeted by PML/
RARa, PR9 cells were treated with 100 mM of ZnSO4 for 4 hr,
a condition known to eventually induce many features similarCto those of APL (Grignani et al., 1993). Also, under this condition,
the amount of PML/RARa induced was more abundant than that
of the endogenous RARa (Figure 1A and Figure S1A, available
online), which might help to minimize the potential interference
resulting from RARa, since a RARa-specific antibody was used
to pull down DNA bound by PML/RARa. The precipitated DNA
was then amplified, labeled, and hybridized to Affymetrix Human
Promoter 1.0R arrays. Based on three biological replicates,
a total of 2979 highly significant ChIP regions (Table S1) were
identified through a model-based analysis of tiling-array algo-
rithm (Johnson et al., 2006). Those ChIP regions, with an average
size of 829 bps, represent 1981 unique RefSeq genes. To
validate the ChIP-on-chip findings, we performed ChIP quantita-
tive PCR (ChIP-qPCR) on DNA samples, precipitated using
either an anti-PML antibody or an anti-RARa antibody, before
and after PML/RARa induction. The PCR was performed with
25 primer pairs corresponding to six previously known targets
of PML/RARa or RARa and 19 randomly chosen regions from
the ChIP population. As illustrated in Figure 1B, enrichment of
all the tested ChIP regions was significantly higher than that of
non-relevant regions in DNA samples precipitated by either the
anti-RARa or the anti-PML antibody after PML/RARa induction,
although the degree of enrichment varied from one ChIP region
to another (top). In contrast, most of the tested ChIP regions
(17/25) were not enriched (<3 folds) in DNA samples precipitated
by the two antibodies before PML/RARa induction (Figure 1B,
bottom). These results indicate that the ChIP regions identified
in our ChIP-on-chip experiments are specifically targeted by
PML/RARa. Interestingly, of the eight ChIP regions whose
enrichments were higher than three folds in DNA samples
precipitated by the anti-RARa antibody before PML/RARa
induction, five corresponded to known targets of RARa, i.e.,
RARb2, ITGB2, IL1B, CEBPE, and CDKN2D, implying that a
relatively small portion of the PML/RARa ChIP regions are
targeted by RARa before expression of PML/RARa.
To provide additional controls, we assessed the expression
level of PML/RARa protein in primary APL blasts, APL-derived
NB4 cells (Lanotte et al., 1991), and a set of PR9 cell samples
treated with varying concentrations of ZnSO4, and we also eval-
uated ChIP enrichment in the cells with graded amounts of PML/
RARa through ChIP-qPCR. As shown in Figure 1C, the amount of
PML/RARa protein in primary APL samples fluctuated over a
relatively wide range, as compared to NB4 cells (left panel).
Meanwhile, the amount of PML/RARa protein in NB4 cells was
approximately equivalent to that in PR9 cells treated with
50 mM to 75 mM of ZnSO4 (Figure 1C, right panel). In ChIP-
qPCR assays (Figure S1B), it was clearly shown that most of
the tested ChIP regions were enriched even in PR9 cells treated
with 50 mM of ZnSO4, in which the amount of PML/RARa was
obviously lower than that in NB4 cells. These results suggest
that the amount of PML/RARa induced by 100 mM of ZnSO4 in
PR9 cells for 4 hr is biologically relevant, allowing the fusion
protein to recognize bona fide binding sites upon its expression
in hematopoietic cells.
Identification of Significantly Enriched Binding Sites
in the PML/RARa ChIP Regions
We used three independent and complementary approaches
to identify significantly enriched transcription factor bindingancer Cell 17, 186–197, February 17, 2010 ª2010 Elsevier Inc. 187
Figure 1. Expression of PML/RARa Protein in PR9, NB4, and Primary APL Cells, and Validation of the PML/RARa ChIP Regions
(A) Induction of the PML/RARa protein in ZnSO4-treated PR9 cells. Western blot analysis was performed on PR9 cells treated with 100 mM ZnSO4 for 4 hr and
untreated PR9 cells. A time series induction of the PML/RARa protein by ZnSO4 is shown in Figure S1A.
(B) Validation of the PML/RARa ChIP regions by ChIP-qPCR assays. ChIP-qPCR was performed on PR9 cells with (top panel) or without (bottom panel) ZnSO4
treatment. Codes for individual ChIP regions are marked underneath and corresponding RefSeq genes are indicated inside the brackets. Negative controls are
marked as C1 to C4. Data are shown as fold enrichment of ChIPed DNA versus input DNA. Error bars represent SD of triplicate measurements. See Table S1 for
a full list of the PML/RARa ChIP regions.
(C, Left) Comparison of the amount of PML/RARa protein between NB4 cells and primary APL blasts (APL1 to APL5). (Right) Dose-dependent induction of PML/
RARa protein in PR9 cells as compared to endogenous PML/RARa in NB4 cells. PR9 cells were treated with increasing concentrations of ZnSO4 (25 mM, 50 mM,
75 mM, or 100 mM) for 4 hr. Western blots were performed using the anti-RARa antibody. The position of PML/RARa protein is indicated by arrowheads.
ChIP-qPCR data obtained from PR9 cells treated with the same graded amounts of ZnSO4 are shown in Figure S1B.
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enumeration-based de novo motif discovery approach (details
in the Supplemental Experimental Procedures) was applied to
uncover consensus motifs with statistical significance. Under
a stringent cutoff (Z score > 10) (Xie et al., 2007), a series of
subsequences were identified (Table S2). By comparing these
subsequences with known TFBSs, we found that consensus
binding sites for PU.1, ETS, and AP-1 were highly significant
(Figure 2A, a). Second, 554 position weight matrices of known
TFBSs from the TRANSFAC database were used to scan the
ChIP regions. The matrices V$PU1_Q6, V$ETS_Q6, and
V$AP1_C ranked at the top of the significant motifs (Figure 2A,
b, and Table S3). Third, in view of the fact that position weight
matrices of canonical RAREs (DR5 or DR2) were not included
in the TRANSFAC database, we performed a direct scanning
for such motifs in the ChIP regions. Canonical RAREs (DR5
plus DR2) even with one random mismatch, however, appeared
to be at a relatively low frequency (13.26%) with a Z score of 9.28
(Figure 2A, c, and Table S4). In contrast, 81.97% of the ChIP
regions contained at least one RAREh site (Z score of 18.23)
(Figure 2A, c). Most of these RAREh-containing ChIP regions
(64.21%) had two ormore RAREh sites with different orientations
and variable spacing in between ranging from a few nucleotides
to many bases (Tables S1 and S4). These results appear to be
consistent with previous findings that PML/RARa binds to
RAREh sites in complex and versatile combinations (Kamashev
et al., 2004; Meani et al., 2005).
Since PU.1 motifs represented the most significant and
abundant binding sites next to RAREh sites in the ChIP regions,
and since the vast majority of PU.1 motif-containing segments188 Cancer Cell 17, 186–197, February 17, 2010 ª2010 Elsevier Inc.(84.24%) had one or more RAREh sites (Figure 2B), we as-
sessed whether the coexistence of PU.1 consensus and
RAREh sites (PU.1-RAREh) within the ChIP regions (an average
size of 829 bp) was of statistical significance. As demonstrated
in Figure 2C, the coexistence of PU.1 and RAREh sites, as
identified by the ChIP-on-chip analysis of PML/RARa, was
highly significant (Z score = 29.40). In contrast, a ChIP-on-
chip analysis of PU.1 under the same condition revealed a
moderate enrichment (Z score = 5.66) of RAREh sites in the
PU.1 ChIP regions (Figure 2D). When the PU.1 ChIP regions
were further divided into those shared with the PML/RARa
ChIP regions and those specific to the PU.1 ChIP regions,
the former, but not the latter, revealed a significant enrichment
of RAREh sites (Z score: 11.34 versus 4.22; Figure 2D). These
observations suggest that RAREh sites may provide a mecha-
nism for PML/RARa to selectively target and modify PU.1-regu-
lated genes.
Selective Recruitment of PML/RARa to PU.1-Bound
Chromatin Regions after PML/RARa Induction
Since PU.1-RAREh sites were highly enriched in the PML/RARa
ChIP regions, we questioned whether PU.1-regulated gene tran-
scription could be influenced by PML/RARa on a large scale. To
test this hypothesis, we first determined whether PU.1 and PML/
RARa were co-associated with chromatin corresponding to the
ChIP regions harboring PU.1-RAREh motifs. As demonstrated
in ChIP-qPCR assays (Figure 3A), all of the tested PU.1-RAREh
ChIP regions were significantly enriched in DNA samples,
precipitated either by the anti-RARa or the anti-PU.1 antibody
from ZnSO4-treated PR9 cells, implicating the coexistence of
Figure 2. Identification of the Significant Motifs
(A) Motif discovery of the PML/RARa ChIP regions by three independent methods. The most significant motifs identified using de novo motif analysis and the
TRANSFAC database are shown in (a) and (b), respectively. The lists of all significant motifs identified using the above two methods are provided in Tables
S2 and S3. Results on scanning of RAREh and canonical RAREs are shown in (c). See Table S4 for a list of the RAREh combinations scanned.
(B and C) Schematic illustration of the PU.1-RAREh-containing PML/RARa ChIP regions. RAREhXPU.1 is ChIP regions containing both RAREh and PU.1 sites.
(D) Schematic illustration of the comparison between PML/RARa ChIP regions and PU.1 ChIP regions. PU.1-ChIPXPR-ChIP is the subpopulation of PU.1 ChIP
regions that overlap with PML/RARa ChIP regions. PU.1-ChIP\PR-ChIP is the subpopulation of PU.1 ChIP regions that do not overlap with PML/RARa ChIP
regions. PU.1 binding sites are defined by V$PU1_Q6 from TRANSFAC with the matrix similarity cutoff of 0.8, while RAREh sites are defined as perfect matches
to RGKTCA consensus sequences.
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observation, we performed sequential ChIP (re-ChIP) assays on
ZnSO4-treated PR9 cells. As demonstrated in both panels of
Figure 3B, the ChIP regions immunoprecipitated with the first
indicated antibody (anti-RARa/anti-PU.1) were re-immunopre-
cipitated with the second indicated antibody (anti-PU.1/anti-
RARa), indicating the binding of PU.1 and PML/RARa to the
same DNA.
To determine whether the binding of PU.1 to the ChIP
regions was before the binding of PML/RARa, we conducted
ChIP-qPCR on DNA samples prepared before and after PML/
RARa induction using specific antibodies against PU.1 and
RARa. As shown in Figure 3C, the difference of ChIP enrich-
ment before and after the ZnSO4 treatment was minimal in
the PU.1 ChIP but dramatic in the PML/RARa ChIP, indicating
the tethering of PML/RARa to chromatin regions pre-bound
by PU.1.
Colocalization of PU.1 and PML/RARa on the same DNA frag-
ments could be fortuitous or might indicate a physical interaction
between the two proteins. To test this, coimmunoprecipitation
(co-IP) assays were conducted using protein lysates from
ZnSO4-treated PR9 cells. As illustrated in Figure 3D, PU.1 was
specifically detected in protein products immunoprecipitated
by either the anti-RARa or the anti-PML antibody (left panel)
and, likewise, PML/RARa was specifically detected in immuno-
precipitates obtained with the anti-PU.1 antibody (right panel),Csuggesting that an interaction between PML/RARa and PU.1
occurred in vivo.
DNA Binding Assessment of PU.1 and PML/RARa
to the PU.1-RAREh ChIP Regions
To further assess PU.1 and PML/RARa binding at the molecular
level, we performed EMSA and DNase I footprinting assays on
PU.1-RAREh-containing promoter sequences. As demonstrated
in Figure 4A, when a 22 bp probe from the ChIP region of HCK
covering the PU.1 motif was incubated with nuclear extracts
from cells transfected with PU.1, specific protein-DNA com-
plexes were observed (lane 2) and were supershifted by the
anti-PU.1 antibody (lane 3), providing evidence that PU.1 binds
to its motif identified in this setting. With increasing amounts
of PML/RARa-containing nuclear extracts, the intensity of
PU.1-DNA complexes decreased (Figure 4A, lanes 6–9), with
concomitant accumulation of isotopic signals at the top of the
gel; this was not seen with control extracts (Figure S2A). These
results suggest that PML/RARa can interact with PU.1 in the
presence of the probe DNA. Furthermore, DNase I footprinting
assays on the ChIP region of NCF4 provided a clear view of
the binding of PU.1 and PML/RARa to a PU.1-RAREh-containing
DNA fragment. As shown in Figure 4B and Figure S2B, in the
presence of PU.1 alone, protection occurred only at the PU.1
motif, whereas in the presence of PML/RARa alone, no protec-
tion occurred at the RAREh sites, indicating that this fragmentancer Cell 17, 186–197, February 17, 2010 ª2010 Elsevier Inc. 189
Figure 3. Molecular Evidence for the Interaction between PML/RARa and PU.1 on the PU.1-RAREh ChIP Regions
(A) Presence of both PU.1 and PML/RARa on the PU.1-RAREh ChIP regions after the induction of PML/RARa in PR9 cells as assayed by ChIP-qPCR. The canon-
ical RARE-containing regions (asterisks) and the non-relevant regions () are included as controls. Data are shown as fold enrichment of ChIPed DNA versus input
DNA. Error bars represent SD of triplicate measurements.
(B) Validation of the co-presence of PML/RARa and PU.1 on the same PU.1-RAREh ChIP regions through re-ChIP assays. ChIP products of the first indicated
antibodies (1st ChIP) from ZnSO4-treated PR9 cells were subjected to immunoprecipitation using the second indicated antibodies (2nd ChIP).
(C) Recruitment of PML/RARa to the PU.1-RAREh ChIP regions pre-bound by PU.1. ChIP-qPCR was performed using the anti-PU.1 and the anti-RARa
antibodies. Data are shown as fold enrichment of ChIPed DNA versus input DNA. Error bars represent SD of triplicate measurements.
(D) Demonstration of the in vivo interaction between PML/RARa and PU.1 in PR9 cells after PML/RARa induction through co-IP assays. Western blots of input
lysates or immunoprecipitates were analyzed using the indicated antibodies.
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protection of the RAREh sites occurred only when both PU.1 and
PML/RARa were present, demonstrating that PU.1 binding is
a prerequisite for PML/RARa binding to its motifs.
Repression of PU.1-Dependent Transactivation
by PML/RARa
Luciferase reporter assays were then conducted on 293T cells
to evaluate the biological relevance of PU.1-RAREh-containing
promoters on PU.1-mediated transactivation in the presence
or absence of PML/RARa. Promoter regions that were tested
included those for SPI1/PU.1, SFRS3, HCK, PSMB10, IRF1,
andNCF4. In addition, a nativeRARb2 promoter with a canonical
RARE and an artificial construct with three RARE copies
(RARE3) were included as controls. As illustrated in Figure 5A,
the PU.1-RAREh promoters shared several common features.
First, promoter activities were significantly enhanced by co-
transfection of PU.1 (Figure 5A, lane 7 versus 1), indicating
PU.1-dependent transactivation of these promoters. Second,
the PU.1-dependent transactivation was effectively suppressed
by cotransfection of PML/RARa (Figure 5A, lane 8 versus 7).
Third, the suppression of PU.1-dependent transactivation by
PML/RARa was relieved by the addition of ATRA (Figure 5A,
lane 9 versus 8), although the efficiency of the relief varied
from one promoter to another. PML/RARa alone (Figure 5A,
lane 3 versus 1) or with the addition of ATRA (lane 4 versus 3)
caused minor/minimal changes in luciferase activity, providing
additional evidence that transactivation of these promoters
was primarily regulated by PU.1. Unlike PML/RARa, RARa had
minimal impact on PU.1-mediated transactivation (Figure 5A,
lane 10 versus 7), and the addition of ATRA resulted in minimal190 Cancer Cell 17, 186–197, February 17, 2010 ª2010 Elsevier Inc.changes (lane 11 versus 10), consistent with the above finding
that the PU.1-RAREh regions were targeted by PML/RARa
rather than RARa.
In contrast to the PU.1-RAREh promoters, both the native
RARb2 promoter and the artificial RARE3 segment revealed
distinct features. For instance, PU.1 alone had minimal impact
on luciferase activities of the RARb2 and RARE3 promoters
(Figure 5A, lane 7 versus 1). However, the suppressive effect
of PML/RARa alone was obvious (Figure 5A, lane 3 versus 1).
Unlike that of the PU.1-RAREh promoters, ATRA-mediated
transactivation of the canonical RARE promoters was signifi-
cantly high in cells cotransfected with PML/RARa (Figure 5A,
lane 4 versus 3), RARa (lane 6 versus 5), or empty vector (reflect-
ing activity of endogenous RARa protein) (lane 2 versus 1),
highlighting the regulatory nature of RAREs on these promoters.
Interestingly, although ATRA-mediated transactivation was evi-
dent on the RAREs, this transactivation was even more
enhanced by cotransfection of PU.1 (Figure 5A, lane 12 versus
2, lane 9 versus 4, and lane 11 versus 6). Although this interesting
observation suggests that the ATRA-dependent transactivation
can be potentiated by other factors, such as PU.1, and thus
adds another feature to RARa-regulated promoters, it remains
to be determined whether PU.1 can physically and functionally
interact with RARa under physiological conditions.
It has been previously shown that PU.1 is a positive regulator
of its own promoter (Chen et al., 1995a). Consistent with this
finding, we also showed that PU.1 bound to its own promoter
(Figure 5A). More importantly, we found that PML/RARa could
bind to the PU.1 promoter, resulting in repression of its transac-
tivation (Figure 5A). Indeed, in line with the previous data (Mueller
et al., 2006), we found that both the mRNA and protein levels of
Figure 4. Molecular Evidence for the DNA Binding of PU.1 and PML/RARa to the PU.1-RAREh ChIP Regions
(A) Demonstration of the interaction between PML/RARa and PU.1 in the presence of DNA by EMSA assays. A PU.1 site-containing probe from theHCK promoter
was used. See Figure S2A for a control experiment showing the PU.1-DNA complex with increasing amounts of control extracts. T, the top of the gel; S, super-
shifted PU.1-DNA complex with the anti-PU.1 antibody; NS, nonspecific complex; PU.1-SF, complex formed by PU.1 with other proteins in the nuclear extracts;
PU.1, gel-shifted complex formed with PU.1 protein; *, complexes formed by proteolytic products of PU.1; F, unbound free probe.
(B) Binding site protection of the NCF4 promoter by DNase I footprinting analysis. The blue traces (left) and green traces (right) represent, respectively, the
fluorescence intensities of the RAREh sites containing NCF4 coding strand (labeled with 50-FAM) and the PU.1 site containing NCF4 non-coding strand (labeled
with 50-HEX), both of whichwere incubated with the nuclear extracts from the 293T cells transfected with PML/RARa, PU.1, or PML/RARa-PU.1. The black traces
represent the fluorescence intensity of the above regions incubated with control nuclear extracts from non-transfected 293T cells. Region I-a is a segment
containing a perfect RAREh motif; region I-b is a segment containing a RAREh motif with one mismatch; region II is a segment containing a PU.1 consensus
site. DNA sequences (bottom) showing three protected regions are underlined. Full-length electropherograms are included in Figure S2B.
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as compared to untreated PR9 cells (Figure 5B). These observa-
tions suggest that downregulation of PU.1 in PML/RARa-posi-
tive cells is probably due to disruption of autoregulated PU.1
expression by PML/RARa.
Functional Assessment of PU.1 and RAREh Motifs
To test whether PU.1 and RAREh sites are responsible for the
observed effects in Figure 5A, we mutated/truncated PU.1
and RAREh sites in PSMB10 and SFRS3 promoters and
measured their luciferase activities. As shown in Figure 5C,
mutation of the PU.1 sites was associated with significant
reduction of PU.1-mediated transactivation (lane 7 versus 2)
and the subsequent effects of PML/RARa (lane 9/7 versus
lane 4/2), highlighting the biological significance of the PU.1
sites in these promoters. Although mutation of the PU.1 site in
the PSMB10 promoter correlated with significant reduction in
PU.1-mediated transactivation, the mutated promoter appeared
to retain some responsiveness; this is likely due to the presence
of unidentified non-canonical PU.1 sites in the promoter. As ex-
pected, absence of the RAREh sites was strongly associatedCwith loss of PML/RARa-mediated transrepression (Figure 5C,
lane 4/2 versus lane 14/12) and loss of ATRA responsiveness
(lane 5/4 versus lane 15/14). This further supports our conten-
tion that ATRA responsiveness of the PU.1-RAREh promoters
is primarily via the formation of the PML/RARa-PU.1 complex
on DNA.
Repression of PU.1-Dependent Transactivation
by PML/RARa in Myeloid Cells
To test whether the results obtained in 293T cells could also be
seen in hematopoietic cells, we performed transfection assays in
myeloid precursor U937 cells, which expressed endogenous
PU.1, using the same set of PSMB10 promoters shown in Fig-
ure 5C. Similar to the result in 293T cells, transactivation of the
wild-type promoter was significantly suppressed by cotransfec-
tion of PML/RARa in U937 cells (Figure 5D, lane 2 versus 1). Also
consistent with the previous observations, mutation of the PU.1
motif (Figure 5D, PU.1-MT) was associated with significant
reduction in induced activity (lane 3 versus 1) as well as signifi-
cant loss of PML/RARa-mediated transrepression (lane 4/3
versus lane 2/1). When the cells were transfected with theancer Cell 17, 186–197, February 17, 2010 ª2010 Elsevier Inc. 191
Figure 5. Evidence for Repression of PU.1-mediated Transactivation by PML/RARa
(A) Luciferase reporter assays on representatives of PU.1-RAREh-containing promoters (SPI1, SFRS3, HCK, PSMB10, IRF1, and NCF4) or canonical
RARE-containing promoters (RARB andRARE3). Reporter plasmids and expression plasmids were cotransfected into 293T cells. SPI1, hematopoietic transcrip-
tion factor PU.1; SFRS3, splicing factor, arginine/serine-rich 3; HCK, hematopoietic cell kinase; PSMB10, proteasome subunit, b type 10; IRF1, interferon
regulatory factor 1; NCF4, neutrophil cytosolic factor 4; RARB, retinoic acid receptor b (RARb2); RARE3, an artificial construct with three RARE copies.
(B) Expression of PU.1 in PR9 and NB4 cells. Real-time RT-PCR (top) and western blot analyses (bottom) were used to quantify PU.1 at both the mRNA and
protein levels. mRNA levels were expressed relative to those in untreated PR9 cells. PR9 cells were treated with ZnSO4 at the indicated time points.
(C) Mutation/truncation analysis of the promoter region of PSMB10 andSFRS3. The PU.1 (gray ellipses) and RAREh sites (gray boxes) present in these constructs
were mutated (X) or truncated, and the resultant constructs were assayed for the reporter gene activity in 293T cells.
(D) Repression of PU.1-mediated transactivation by PML/RARa in myeloid U937 cells. The same constructs of PSMB10 used in (C) were tested.
(E) Requirement of both the DNA binding and protein-protein interaction domains for PML/RARa to function as an effective repressor. Expression plasmids
encoding PML/RARa/DCC and PML/RARa/DR were used.
(F) Involvement of RXR in the PML/RARa ChIP regions. ChIP-qPCR was performed on chromatin prepared from ZnSO4-treated PR9 cells using the antibodies
specific to RXRa, RARa, and PU.1, respectively. Luciferase activities in (A) and (C)–(E) are normalized for transfection efficiency by co-transfection with a Renilla
construct, and values are the mean ± SD obtained from at least three independent experiments. Results from real-time RT-PCR in (B) are normalized to GAPDH
and show the mean of three replicates ± SD. Data in (F) are shown as fold enrichment of ChIPed DNA versus input DNA and error bars represent SD of triplicate
measurements.
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Genome-wide Recognition of PML/RARa Binding Sitespromoter devoid of RAREh sites (Figure 5D, RAREh-MT), the
PML/RARa-mediated transrepression was essentially abro-
gated (lane 6/5 versus lane 2/1), indicating that the binding of192 Cancer Cell 17, 186–197, February 17, 2010 ª2010 Elsevier Inc.PML/RARa to RAREh sites is required for the transrepression.
In sum, the data obtained in hematopoietic cells confirm those
obtained in 293T cells, supporting the notion that both PU.1
Figure 6. Selective Targeting of PU.1-regu-
lated Genes by PML/RARa in NB4 Cells
and Primary APL Blasts
(A) Recruitment of both PU.1 and PML/RARa to
the PU.1-RAREh-containing PML/RARa ChIP
regions in NB4 cells by ChIP-qPCR assays. Data
are shown as fold enrichment of ChIPed DNA
versus input DNA. Error bars represent SD of trip-
licate measurements.
(B) Demonstration of the in vivo interaction
between PML/RARa and PU.1 in NB4 cells by
co-IP assays. Western blots of input lysates or
immunoprecipitates were analyzed using the indi-
cated antibodies.
(C) Distribution of PML/RARa and PU.1 in primary
APL blasts. Confocal immunofluorescence assays
were performed using anti-PU.1 (green) and anti-
PML (red) antibodies. Scale bars, 5 mm. Confocal
microscopic images of blast cells from additional
five primary APL patients are included in
Figure S3.
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Genome-wide Recognition of PML/RARa Binding Sitesand RAREh sites play important roles in PML/RARa-mediated
transcriptional repression in APL.
Requirement of Both Protein-Protein Interaction
and DNA Binding for PML/RARa to Act as
an Effective Repressor on PU.1-RAREh Promoters
We have shown that PU.1 and PML/RARa interact to form
a transcriptional complex. In an attempt to identify the regions
of PML/RARa important in forming this complex, we tested two
truncated forms of PML/RARa in luciferase reporter assays,
i.e., PML/RARa/DCC, in which the coiled-coil domain is
deleted (Jansen et al., 1995), and PML/RARa/DR, in which
the DNA binding domain is deleted (Grignani et al., 1996). As
demonstrated in Figure 5E, deletion of the coiled-coil domain
was sufficient to abolish the repressive effects of PML/RARa
on PU.1-dependent transactivation (lane 5 versus 3), while
deletion of the DNA binding domain of PML/RARa had a
moderate effect on mediating transrepression (lane 7 versus
3). However, loss of the DNA binding of PML/RARa was highly
correlated with loss of the responsiveness of the promoters toCancer Cell 17, 186–197,ATRA (Figure 5E, lane 8 versus 7), con-
sistent with the results shown in Fig-
ure 5C in which promoters without
RAREh sites were used.
Involvement of RXR in the PML/
RARa-PU.1-Bound ChIP Regions
Since RXR is known to be a crucial
component of PML/RARa complexes
(Zhu et al., 2007; Perez et al., 1993), we
then assessed whether RXR was present
in the PML/RARa-PU.1-bound ChIP re-
gions. As evaluated by ChIP-qPCR using
a RXRa-specific antibody, RXR was
indeed present in some, but not all, of
the tested ChIP regions (Figure 5F). This
is consistent with the previous notion
that PML/RARa exists in multiple formsof complexes, including PML/RARa homodimers devoid of
RXR and oligomers and heterodimers containing RXR.
Molecular Evidence for Selective Targeting
of PU.1-Regulated Genes by PML/RARa
in APL-Derived NB4 Cells and Primary APL cells
With the model system of PR9 cells, we have identified PU.1-
RAREh-containing promoters as important targets of PML/
RARa. To test whether this finding is relevant to APL, we first
conducted ChIP-qPCR and co-IP assays on the APL-derived
cell line NB4. As demonstrated in the ChIP-qPCR data of NB4
cells (Figure 6A), most of the tested ChIP regions were signifi-
cantly enriched by either the anti-RARa or the anti-PU.1 anti-
body, indicating the co-presence of PU.1 and PML/RARa on
chromatin DNA corresponding to the ChIP regions. Moreover,
co-IP assays on NB4 cells (Figure 6B) revealed similar phe-
nomena as those shown in Figure 3D, i.e., PML/RARa was
immunoprecipitated by the anti-PU.1 antibody and vice versa,
demonstrating that PML/RARa interacts with PU.1 in NB4 cells
as well. In addition, confocal microscopic images of PU.1 andFebruary 17, 2010 ª2010 Elsevier Inc. 193
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194 Cancer Cell 17, 186–197, February 17, 2010 ª2010 Elsevier Inc.PML/RARa immunofluorescence, in NB4 and primary APL cells,
allowed us to visualize in situ spatial relationships between the
two proteins. As illustrated in Figure 6C and Figure S3, PU.1
and PML/RARa colocalized on microspeckles. It is important
to note that the colocalization appears to occur on some rather
than all of the microspeckles, further supporting the notion that
PML/RARa selectively interacts with PU.1 in APL cells.
Evidence for Transcriptional Repression/ATRA
Responsiveness of Genes Corresponding
to the PU.1-RAREh ChIP Regions in APL
Still, an important question that remains to be addressed is
whether genes corresponding to PML/RARa ChIP regions,
particularly those corresponding to PU.1-RAREh ChIP regions,
are transcriptionally suppressed in primary APL cells. To answer
this question, we conducted a gene set-based analysis by
comparing RefSeq genes corresponding to the total PML/
RARa ChIP regions and the PU.1-RAREh ChIP regions with
gene sets representing the differentially regulated genes from
APL models/APL clinical samples. The gene sets were con-
structed from microarray data on PR9 cells after PML/RARa
induction (Alcalay et al., 2003), clinical APL samples (Valk
et al., 2004), ATRA-treated NB4 cells (this study, GEO accession
number GSE19201), and ATRA-treated primary APL cells (Meani
et al., 2005). We also included in the analysis a data set (PR_DN
and RA_UP) created by selecting genes both downregulated in
APL/ZnSO4-treated PR9 cells and upregulated in ATRA-treated
NB4/APL cells. There has been a long-standing assumption that
downregulation of genes in APL cells is largely due to PML/
RARa-mediated transcriptional repression and upregulation of
genes in ATRA-treated APL cells is a consequence of the relief
of that repression. As illustrated in Table 1, genes corresponding
to both total and PU.1-RAREh ChIP regions were highly overrep-
resented (Z score > 10) in the gene sets relevant to PML/RARa-
mediated transcriptional repression (including the gene sets
downregulated in APL samples and ZnSO4-treated PR9 cells,
i.e., APL_DN and PR9_Zn_DN) and in those relevant to the
responsiveness to ATRA (including those upregulated in ATRA-
treated primary APL cells and ATRA-treated NB4 cells, i.e.,
APL_RA_UP and NB4_RA_UP). Through this analysis, we found
that a significant portion of genes represented by the identified
ChIP regions, especially those containing PU.1-RAREh sites,
were transcriptionally suppressed in APL and/or reactivated
upon ATRA treatment.
To test whether the genes corresponding to PU.1-RAREh
ChIP regions and suppressed in APL and/or reactivated upon
ATRA treatment (see Table S5 for the gene list) are functionally
relevant to myeloid differentiation, we performed Gene Ontology
(GO) enrichment analysis (http://www.pantherdb.org/). As illus-
trated in Table S6, significant enrichment was observed on GO
terms involved in various aspects of myeloid differentiation,
as highlighted by transcription factors, granulocyte-mediated
immunity, and defense activities and some other myeloid-asso-
ciated cascades. For example, transcription factors JUNB, IRF1,
BHLHB2, ID2, and PU.1 are known to be early-lineage regulators
of myelopoiesis and thus reduced levels of these genes/proteins
are possibly consistent with the blocked differentiation charac-
teristic of APL. Other significantly overrepresented GO cate-
gories included cell proliferation and differentiation, apoptosis,
Cancer Cell
Genome-wide Recognition of PML/RARa Binding Sitescell cycle control, and signal transduction, all of which may
collectively contribute to uncontrolled proliferation and
decreased apoptosis in leukemic cells.
DISCUSSION
PML/RARa is the initiating factor in the development of APL and
has a number of distinct features. In normal hematopoietic pre-
cursor CD34+ Lin cells, the introduction of PML/RARa induces
a differentiation block and promotes cell survival through amulti-
step process (Grignani et al., 2000). Similarly, the expression of
this oncoprotein in hematopoietic PR9 cells induces many
phenotypic changes like those in APL, such as inability to differ-
entiate under certain stimuli, increased proliferation and sensi-
tivity to ATRA (Grignani et al., 1993). Also, the expression of
PML/RARa in murine bone marrow eventually causes disease
with features characteristic of APL. Interestingly, a higher level
of PML/RARa appears to be required during the initiation stage
of oncogenic activities (Grignani et al., 2000; Nasr et al., 2008).
Another interesting feature of this oncogenic protein is that its
transcriptional repression effect can be relieved by ATRA, result-
ing in reactivation of genes essential for definitive myeloid differ-
entiation. Exactly how PML/RARa exerts all of its effects on APL
has been a continuing area of research, particularly as interfer-
ence of RARa-mediated transcription alone does not recapitu-
late the disease phenotype. Based on this latter observation, it
has been proposed that PML/RARa not only represses RAR
signaling but also interferes with other myeloid essential tran-
scription factors. In our work, we have investigated the early
molecular effects of PML/RARa in hematopoietic progenitor
cells and identified PU.1 as a factor that directs binding of
PML/RARa to nearby RAREh sites, and in so doing creates a
PML/RARa-PU.1 complex.
PU.1 has been identified as an important transcription factor in
normal hematopoiesis and in generation of myeloid leukemias
through disruption of its function (Tenen, 2003). Over a decade
ago, PU.1 was reported to be expressed at high levels in granu-
locytic cells and was associated with the differentiation of
myeloid cells from granulocytic precursors into mature neutro-
phils (Chen et al., 1995b). More recently, studies based on
various in vitro and in vivo models have further demonstrated
that PU.1 promotes the differentiation of committed myeloid
progenitors (Rosenbauer and Tenen, 2007). Functional disrup-
tion of PU.1 or graded reduction in its expression may block
myelomonocytic differentiation or maturation, resulting in accu-
mulation of myeloid blasts and thus genesis of myelogenous
leukemia in animal models (Dakic et al., 2005; Iwasaki et al.,
2005). Overexpression of PU.1 has been shown to rescue
myeloid differentiation in AML blasts that carry a mutant form
of PU.1 (Rosenbauer et al., 2004).
In APL, expression of PU.1 is suppressed in leukemic cells.
Treatment of these cells with ATRA restores PU.1 expression
and induces neutrophil differentiation (Mueller et al., 2006). Im-
portantly, conditional expression of PU.1 in PML/RARa leukemic
cells is sufficient to induce neutrophil differentiation (Mueller
et al., 2006), revealing biological effects similar to ATRA. With
transgenic mice models, the penetrance rate of APL develop-
ment is significantly increased in offspring once PML/RARa
mice are crossed with PU.1+/ mice (Walter et al., 2005). ToCdate, it is still unclear whether such crosstalk between PU.1
and PML/RARa was due to direct interaction of the two proteins
or to indirect effects.
In the work presented here, we provide evidence that PU.1
and PML/RARa are in a transcriptional complex. The initiating
factor for the complex is the recruitment of PML/RARa protein
to chromatin DNA that contains both PU.1 and RAREh sites
and has been bound by PU.1. The resulting DNA-bound PU.1-
PML/RARa complex causes repression of PU.1-regulated
genes. Through reporter assays using truncated proteins and
promoters with mutant DNA binding sites, we have found that
both protein-protein and DNA binding domains of PML/RARa
are important for the effect, as are the PU.1 and RAREh sites.
The formation of PU.1-PML/RARa complexes on DNA and
thus the selective targeting of PU.1-regulated promoters can
be complex, requiring multiple essential elements. An obvious
one is the presence of PU.1 motifs and thus the pre-bound
PU.1 protein on the DNA region. The second one is the nearby
presence of RAREh sites. These RAREh sites may form various
DRs, everted repeats, and inverted repeats with widely variable
spacing in between (see Table S4). However, due to the diversity
and complexity of the RAREh-formed combinations, it is ex-
tremely challenging to extract some common features, except
for RAREh, out of these DRs, everted repeats, and inverted
repeats. Additional elements yet to be identified probably
include histone modifications involved in the ChIP regions, since
certain types of modifications appear to be a prerequisite for
transcription factor binding (Guccione et al., 2006).
Our findings shed light on the functional correlation between
PML/RARa and PU.1 in APL and raise some interesting issues.
First, the promoter of PU.1 itself is targeted by PML/RARa,
resulting in downregulation of PU.1. Reduced PU.1 in APL may
fail to effectively activate its downstream target genes, suggest-
ing that downregulated PU.1 targets in APL include not only
those targeted by PML/RARa (i.e., containing PU.1-RAREh sites)
but also those not targeted by PML/RARa (i.e., containing PU.1
motif only). Such an assumption is supported by the gene set
analysis (Table 1), in which results revealed by the PU.1 ChIP
regions are highly similar to those revealed by the PML/RARa
ChIP regions. It may also explain why a dramatic effect of differ-
entiation can be obtained in APL cells simply by restoring PU.1
expression (Mueller et al., 2006).
Another issue is whether PML/RARa exerts its oncogenic
effect by targeting PU.1-regulated genes in the context of
myeloid cells. Evidence that addresses this issue is that we
have successfully detected the interaction between PML/RARa
and PU.1 in hematopoietic PR9/NB4 cells through co-IP assays,
but we have failed to do so in non-hematopoietic 293T cells co-
expressing the two proteins (data not shown). The latter result is
in accordance with previously published data (Yoshida et al.,
2007). Accordingly, these data may also suggest that additional
cofactors or modifications required for PML/RARa to interact
with PU.1 are yet to be identified.
It has been previously shown that PU.1 is important in the
pathogenesis of APL. However, the how and why were not
known. Here we provide evidence for a direct interaction
between PU.1 and PML/RARa in APL cells and the subsequent
effect of this complex on PU.1-regulated genes. PU.1 is known
to regulate genes by interacting, in either a synergistic or anancer Cell 17, 186–197, February 17, 2010 ª2010 Elsevier Inc. 195
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EBPa, c-Jun, AML-1, IRF4, and GATA-1 (Tenen, 2003). Indeed,
we found that the potential binding sites of many other transcrip-
tion factors were enriched in PML/RARa ChIP regions, but at a
moderate to low frequency (Table S3). While we have shown
the importance of the interaction between PU.1 and PML/
RARa in the pathogenesis of APL, it remains to be determined
whether other yet unidentified transcription factors may also
contribute to the differentiation block at the promyelocytic stage.
However, data presented in this study provides a roadmap to
future work and a more comprehensive understanding of APL.EXPERIMENTAL PROCEDURES
Cell Lines, Antibodies, and Reagents
PR9 is a PML/RARa-inducible model (Grignani et al., 1993) constructed from
U937, a myeloid precursor cell line without the t(15;17) translocation but
expressing many proteins important in myeloid development, including
PU.1. To avoid the potential bias of clonal variations in culture, a single-cell
subclone was selected.
NB4 is an APL-derived cell line, carrying the t(15;17) translocation and
expressing the PML/RARa fusion protein (Lanotte et al., 1991).
The antibodies used are as follows and were purchased from Santa Cruz
Biotechnology: PML (PG-M3), PML (H-238 x), RARa (C-20 x), and PU.1 (T-
21 x). The rabbit IgG (ab46540) and anti-rabbit IgG HRP-linked antibodies
(#7074) were obtained from Abcam and Cell Signaling, respectively.
Protein A Sepharose beads were purchased from GE Healthcare. ATRA
(Sigma-Aldrich) was dissolved in ethanol as a stock solution at 1 mM and
ZnSO4 (Sigma-Aldrich) was dissolved in sterile water as a stock solution at
100 mM.
Patient Samples
APL blasts were obtained at disease onset from bone marrow samples of
newly diagnosed patients with over 85% abnormal blasts and promyelocytic
cells in their bone marrow. Informed consent was obtained from all patients
according to procedures approved by the institutional review board fromRuijin
Hospital, affiliated with Shanghai Jiao Tong University School of Medicine.
ChIP-on-Chip and Data Analysis
ChIP was performed according to the Affymetrix protocol as described
previously (Carroll et al., 2005). The microarrays used were Affymetrix Human
Promoter 1.0R Arrays, which cover 7.5–10 kb upstream through 2.45 kb
downstream of transcriptional start sites for over 25,500 human genes. Three
independent replicates were performed according to the instructions of the
manufacturer.
ChIP-on-chip data were analyzed using a model-based analysis of tiling-
array algorithm (Johnson et al., 2006) at the p value cutoff of 105 with input
DNA as control. De novo motif analysis was performed by an enumeration-
based method. In addition, TRANSFAC motifs, RAREh sites, and RAREh
combinations were also evaluated. Details are available in Supplemental
Experimental Procedures. Statistical significance of motifs was assessed by
the binomial test and represented as Z scores.
Immunofluorescence Microscopy, Co-IP, and Western Blotting
Immunofluorescence microscopy, co-IP, and western blotting were per-
formed as previously described with some modifications. Details are available
in Supplemental Experimental Procedures.
EMSA and DNase I Footprinting Assay
EMSAs were conducted using a PU.1 site-containing HCK promoter in
the presence of either nuclear extracts from transfected 293T cells or in vitro
translation products. DNase I footprinting was performed using the Core Foot-
printing System (Promega) and analyzed with the 3730 DNA Analyzer (Applied
Biosystems). Details are available in Supplemental Experimental Procedures.196 Cancer Cell 17, 186–197, February 17, 2010 ª2010 Elsevier Inc.Luciferase Reporter Assay
HEK293T cells were transfected using Lipofectamine 2000 (Invitrogen). U937
cells were transiently transfected using the Amaxa Nucleofector device
(program V-01) with Nucleofector Kit V (Amaxa Biosystems). Luciferase activ-
ities were analyzed using Dual-Luciferase Reporter Assay System (Promega).
Details are available in Supplemental Experimental Procedures.
Gene Set Analysis
A gene set was defined as a group of genes with same/similar biological
features under a given condition. Statistical significance was assessed by
the binomial test. Details are available in Supplemental Experimental Proce-
dures.
Expression Microarrays
The expression microarrays used were Affymetrix hgu133Plus2. All experi-
ments were performed according to the manufacturers’ instructions. Details
for microarray data analysis are available in Supplemental Experimental
Procedures.
ACCESSION NUMBERS
Microarray gene expression data and ChIP-on-chip data are available at NCBI
Gene Expression Omnibus under accession numbers GSE19201 and
GSE19202, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, six tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:
10.1016/j.ccr.2009.12.045.
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